Physician

Mark Warren, M.D.

According to 2025 Medicare claims, Mark Warren, M.D. (NPI: 1629073010) practices endocrinology in the Greenville, NC market, with the plurality of this provider's patient population coming from Pitt, NC. This provider's primary affiliated billing organization is PHYSICIANS EAST, P.A. (NPI: 1598761967; TIN: 561968491) and primary practice location at 27834-5194. Warren is affiliated with the Aledade A4548 NC Legacy MSSP Enhanced (ACO ID: A4548), participating under the MSSP model.

Warren's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 925 traditional Medicare patients, billed 55,297 HCPCS/CPT codes, and received $834,901 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 12,505 prescription claims across 816 beneficiaries totaling $5,085,627 in drug costs, led by Ozempic (Semaglutide). DME data shows 1,974 claims. Open Payments data shows 323 records totaling $766,557. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $418,919 to $834,901. Similarly, Part D prescription costs have risen steadily, from $2,329,274 to $5,085,627. For DME billing, reported payments moved from a lower plateau to a higher plateau, from $129,383 to $525,868.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,288	34,384	$418,919
2016	1,283	33,120	$453,841
2017	1,291	37,136	$421,720
2018	1,229	31,588	$419,651
2019	1,243	44,343	$505,500
2020	1,226	43,322	$527,904
2021	1,143	36,947	$521,316
2022	1,031	34,064	$496,111
2023	1,001	46,386	$546,597
2024	925	55,297	$834,901

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	629	12,696	$2,329,274
2016	668	12,702	$2,786,610
2017	674	12,952	$3,172,290
2018	710	12,936	$3,770,002
2019	748	12,442	$4,011,312
2020	767	12,267	$3,991,496
2021	755	11,783	$4,206,300
2022	747	11,342	$4,713,025
2023	768	12,087	$5,445,587
2024	816	12,505	$5,085,627

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	871	2,376	$180,779
2016	874	2,337	$175,642
2017	879	2,224	$273,676
2018	769	2,497	$377,328
2019	676	2,481	$461,245
2020	647	2,581	$538,244
2021	595	2,746	$573,883
2022	567	2,726	$555,370
2023	547	2,663	$552,210
2024	536	1,974	$604,862

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	584	1,101	$90
84443	Blood test, thyroid stimulating hormone (tsh)	420	581	$16
83036	Hemoglobin a1c level	394	837	$10
84439	Thyroxine (thyroid chemical), free	419	571	$9
36415	Insertion of needle into vein for collection of blood sample	456	702	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ozempic	Semaglutide	821	31,943	$1,044,661
Korlym	Mifepristone	17	510	$547,901
Tresiba Flextouch U-200	Insulin Degludec	261	9,721	$336,723
Trulicity	Dulaglutide	235	8,716	$289,146
Jardiance	Empagliflozin	226	10,810	$206,190

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4239	Supply allowance for non-adjunctive, non-implanted continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service	N	168	772	$332,263
J1817	Insulin for administration through dme (i.e., insulin pump) per 50 units	N	40	196	$80,062
E0784	External ambulatory infusion pump, insulin	Y	28	204	$68,091
A4224	Supplies for maintenance of insulin infusion catheter, per week	N	67	198	$48,610
A4238	Supply allowance for adjunctive, non-implanted continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service	N	25	96	$46,034

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	188	$65,630	Amgen Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	135	$700,928	Boehringer Ingelheim Pharmaceuticals, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mark Warren, M.D.?

Tedicare shows public-source Medicare data for Mark Warren, M.D. (NPI 1629073010), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mark Warren, M.D. have ACO affiliation data?

Mark Warren, M.D. is shown with ACO affiliation data for Aledade A4548 NC Legacy MSSP Enhanced (MSSP, ACO ID A4548).

What billing organization is linked to Mark Warren, M.D.?

Mark Warren, M.D. is linked to PHYSICIANS EAST, P.A. (billing NPI 1598761967) in the available physician profile data.

Does Mark Warren, M.D. have Open Payments data?

Mark Warren, M.D. has 323 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.